|Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQB: LXRP) Oral CBD Product to Be Tested by the University of British Columbia|
- The University of British Columbia (UBC) will conduct a double-blind study of Lexaria’s TurboCBD™ oral ingestion product
- TurboCBD™ masks foul tastes, protects pharmaceutical ingredients during stomach passage and increases intestinal absorption by 5-10x
- The UBC study will include 24 volunteers and test their cognitive and cardiovascular function after single doses and after seven days of administration
Traditionally, cannabidiol (CBD) is ingested via inhalation, which can harm the lungs, and many edible products contain unwanted sugars or sweeteners. Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) has revolutionized oral intake with its TurboCBD™ product. Engineered to increase absorption through the intestinal tract, without active compounds destroyed by stomach acid or broken down by the liver, the product also masks the flavor of compounds with undesirable tastes. In August 2017, the University of British Columbia (UBC) announced (http://nnw.fm/3GYyd) that it will conduct the first clinical study of the high-absorption product while evaluating its effects on cognitive function and cardiovascular health of human volunteers.
Currently, Lexaria is the only company to have been awarded a patent for delivery of ingestible non-psychoactive cannabinoids. It holds patents in the U.S. and Australia, and more are pending in over 40 other countries. The upcoming UBC study will be double-blind and placebo controlled. Researchers will measure the effects after a single dose and after seven days of daily doses. The 24 volunteers will consist of young and old individuals, whose glucose, blood pressure, vascular function, cognition, and physical performance will be measured. Blood samples, exercise tests, heart rate, respiration, and neuropsychological tests, among other measurements, will be conducted as well. These tests will provide a complete set of pharmacokinetic and pharmacodynamic performance data of Lexaria’s TurboCBD™.
Regarding the expected outcome of the study, professor Philip Ainslie, PhD, stated in the recent report, “…To quantify the pharmacokinetics of TurboCBD™ will allow us to make informed recommendations of optimum dosing in order to improve vascular health and performance throughout healthy aging. Once we understand these processes better, the applications to various clinical populations can then be explored…”
Details of the test results are expected to be released once the study is completed and the data are interpreted.
According to Lexaria, its “plant-to-bloodstream” product amplifies intestinal absorption by 5-10x. It uses fatty acids, which combine with the active pharmaceutical ingredient to block them from bitter taste receptors on the tongue. Active ingredients are protected by lipids as they pass through the stomach. In the small intestine, long chain fatty acids are absorbed directly into the lymphatic system, while medium chain fatty acids are absorbed via the liver.
An August 2015 in vitro absorption study, conducted in a third party lab, found a 499 percent increase in CBD bioabsorption in the intestines. A human focus study in March 2016 revealed the onset of THC effects in 15 to 20 minutes, while test subjects praised the taste of the product. The company also entered into a collaborative research agreement with Canada’s National Research Council, which was signed in February 2017.
For more information, visit the company’s website at www.LexariaEnergy.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer